The present research showed significant positive correlations between pretreatment concentrations of circulating TGF-β1 and maximum GU toxicity grades and between TGF-β1 concentrations measured after the 25th fraction and GU toxicity grades after this fraction, in patients with prostate cancer undergoing curative radiotherapy. The gene discussed is TGFB1; the disease is prostate cancer.